BioMarin Pharmaceutical Inc

자세한 내용은 BioMarin Pharmaceutical Inc 회사

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

회사 정보

종목 코드 BMRN

회사 이름BioMarin Pharmaceutical Inc

상장일Jul 23, 1999

CEOMr. Alexander Hardy

직원 수3040

유형Ordinary Share

회계 연도 종료Jul 23

주소770 Lindaro Street

도시SAN RAFAEL

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호94901

전화14155066700

웹사이트https://www.biomarin.com/

종목 코드 BMRN

상장일Jul 23, 1999

CEOMr. Alexander Hardy

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

62.99K

-53.04%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

46.81K

+61.08%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

Ms. Erin Burkhart

Group Vice President, Chief Accounting Officer

14.18K

-16.41%

Dr. Athena M. Countouriotis, M.D.

Independent Director

8.83K

+305.05%

Ms. Barbara W. Bodem

Independent Director

8.83K

+305.05%

Ms. Elizabeth Mckey Anderson

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

62.99K

-53.04%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

46.81K

+61.08%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

사업별USD

이름

수익

비율

Voxzogo

213.75M

29.10%

Vimizim

188.35M

25.64%

Naglazyme

114.29M

15.56%

Palynziq

93.27M

12.70%

Aldurazyme

48.98M

6.67%

Other

76.01M

10.35%

지역별USD

이름

수익

비율

United States

241.69M

32.90%

Europe

229.58M

31.25%

Rest of the world

126.11M

17.17%

Latin America

88.28M

12.02%

ALDURAZYME net product revenues marked by Sanofi

48.98M

6.67%

사업별

지역별

사업별USD

이름

수익

비율

Voxzogo

213.75M

29.10%

Vimizim

188.35M

25.64%

Naglazyme

114.29M

15.56%

Palynziq

93.27M

12.70%

Aldurazyme

48.98M

6.67%

Other

76.01M

10.35%

주식 보유 통계

마지막 업데이트: Sun, May 18

주주

주주 유형

주주

비율

The Vanguard Group, Inc.

9.87%

BlackRock Institutional Trust Company, N.A.

9.45%

PRIMECAP Management Company

9.27%

Dodge & Cox

7.80%

Viking Global Investors LP

5.63%

Other

57.99%

주주

비율

The Vanguard Group, Inc.

9.87%

BlackRock Institutional Trust Company, N.A.

9.45%

PRIMECAP Management Company

9.27%

Dodge & Cox

7.80%

Viking Global Investors LP

5.63%

Other

57.99%

주주 유형

주주

비율

Investment Advisor

48.68%

Investment Advisor/Hedge Fund

35.44%

Hedge Fund

8.14%

Pension Fund

2.77%

Sovereign Wealth Fund

2.02%

Research Firm

1.30%

Bank and Trust

1.11%

Individual Investor

0.75%

Venture Capital

0.26%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

1323

192.81M

100.54%

-18.92M

2025Q1

1355

191.53M

99.87%

-20.72M

2024Q4

1336

190.53M

99.88%

-17.50M

2024Q3

1308

188.26M

98.81%

-22.17M

2024Q2

1293

192.58M

101.18%

-14.21M

2024Q1

1278

194.24M

102.38%

-11.23M

2023Q4

1294

193.16M

102.42%

-3.22M

2023Q3

1275

188.66M

100.18%

-4.68M

2023Q2

1283

185.80M

98.76%

-8.08M

2023Q1

1274

186.38M

99.36%

-9.64M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

The Vanguard Group, Inc.

18.92M

9.87%

-369.57K

-1.92%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

18.12M

9.45%

-16.94K

-0.09%

Mar 31, 2025

PRIMECAP Management Company

17.77M

9.27%

-415.89K

-2.29%

Mar 31, 2025

Dodge & Cox

14.96M

7.8%

+209.00K

+1.42%

Mar 31, 2025

Viking Global Investors LP

10.80M

5.63%

+289.51K

+2.75%

Mar 31, 2025

Capital Research Global Investors

9.15M

4.77%

-3.84M

-29.57%

Mar 31, 2025

State Street Global Advisors (US)

8.46M

4.41%

-649.18K

-7.12%

Mar 31, 2025

Columbia Threadneedle Investments (US)

3.62M

1.89%

-171.27K

-4.52%

Mar 31, 2025

Norges Bank Investment Management (NBIM)

3.57M

1.86%

-49.67K

-1.37%

Dec 31, 2024

Elliott Management Corporation

3.50M

1.83%

--

Mar 31, 2025

59.500USD

BioMarin Pharmaceutical Inc

59.500

개요

회사

금융